Evolution of anticancer drug discovery and the role of cell-based screening

Journal of the National Cancer Institute

Volumn 94, Issue 2, 2002, Pages 78-79

  Balis, Frank M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CAMPTOTHECIN; CYCLIN DEPENDENT KINASE INHIBITOR; DACTINOMYCIN; EPIPODOPHYLLOTOXIN; IMATINIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RETINOIC ACID; TAXANE DERIVATIVE; VINCA ALKALOID;

CARCINOGENESIS; CELL MEDIATED CYTOTOXICITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; EDITORIAL; GASTROINTESTINAL TUMOR; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA P 388 CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

EID: 0037116626     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.2.78     Document Type: Editorial

References (19)

1. Treatment of acute promyelocytic leukemia with all-trans retinoic acid. A five-year experience
2. All-trans-retinoic acid in acute promyelocytic leukemia
3. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
4. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
5. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: A phase I study
6. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
7. An information-intensive approach to the molecular pharmacology of cancer
8. How many mutations are required for tumorigenesis? Implications from human cancer data
9. Choosing anticancer drug targets in the postgenomic era
10. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
11. Drug discovery: A historical perspective
12. Anticancer drug targets: Cell cycle and checkpoint control
13. Anticancer drug targets: Growth factors and growth factor signaling
14. Apoptosis and cancer drug targeting
15. Mechanism-based target identification and drug discovery in cancer research
16. Molecules for the millennium: How will they look? New drug discovery year 2000
17. Cell-based assays for identification of novel double-strand break-inducing agents
18. Integrating genetic approaches into the discovery of anticancer drugs
19. Molecular targets in cancer drug discovery: Cell-based profiling